Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651272 · ClinicalTrials.gov registry record · Phase 2
Macitentan in Pulmonary Hypertension of Sickle Cell Disease
A Phase 2 study, sponsored by Boston University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02651272 is a Phase 2 study that was terminated before completion, run by Boston University. The registered enrollment target is 4 participants.
The verdict
NCT02651272, a Phase 2 study, was terminated before completion, sponsored by Boston University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects. Study participation for each subject will last approximately 24 weeks from screening to end of treatment follow-up.
Interventions
- DRUG macitentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02651272
The ClinicalTrials.gov registry entry for NCT02651272 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which macitentan is the first listed.
NCT02651272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02651272 about?
NCT02651272 is a clinical study titled "Macitentan in Pulmonary Hypertension of Sickle Cell Disease". This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects. Study participation for each subject will last approximately 24 weeks from screening to end of treatment follow-up.
What is the current status of trial NCT02651272?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-07. Estimated completion is 2019-12-18.
What interventions are being tested in trial NCT02651272?
The interventions under investigation include: macitentan (DRUG).
Who is sponsoring clinical trial NCT02651272?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.